Autoimmune Reactions in a Patient with Malignant Insulinoma Treated by Multiple Low Dose Streptozotocin*)
- 1 February 1990
- journal article
- research article
- Published by Georg Thieme Verlag KG in Experimental and Clinical Endocrinology & Diabetes
- Vol. 95 (01) , 77-82
- https://doi.org/10.1055/s-0029-1210937
Abstract
A 66-year-old female patient with a malignant insulinoma was treated with streptozotocin (STZ; Zanosar) in 5 cycles every 4 weeks as 5 day courses with an intravenous dosage of 850 mg per day. Under this treatment hypoglycemic episodes decreased continously in number as well as severity and — after a delay of 12 months after the last treatment — an overt diabetes mellitus appeared. Plasma insulin concentrations dropped immediately after starting of STZ therapy. On the other hand, islet cell surface antibodies and their complement-dependent cytotoxicity increased continously, being at their highest 6 months after termination of STZ treatment. Thus, STZ is able to induce a specific immune response against islet cells with a progressive damage of malignant insulin producing cells.Keywords
This publication has 5 references indexed in Scilit:
- Measurement of Insulin in Human Sera Using a New RIA Kit. 1. Insulin Determination in the Absence of Insulin Antibodies — Conventional Assay and Micro Modification2)Experimental and Clinical Endocrinology & Diabetes, 1987
- Treatment with anti-T-lymphocyte antibodies prevents induction of insulitis in mice given multiple doses of streptozocinDiabetes, 1987
- STUDIES ON THE TISSUE-DISPOSITION AND FATE OF [14C]STREPTOZOTOCIN WITH SPECIAL REFERENCE TO THE PANCREATIC ISLETSActa Endocrinologica, 1978
- Streptozotocin-Induced Pancreatic Insulitis: New Model of Diabetes MellitusScience, 1976
- Pancreatic Islet Cell CarcinomaAnnals of Internal Medicine, 1973